title: Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group.
abstract: OBJECTIVE
  This review characterized cases of secondary acute myelogenous leukemia (AML) occurring after treatment of renal neoplasms on protocols of the National Wilms Tumor Study Group (NWTSG) between October 1969 and December 1991.
  
  
  METHODS
  The NWTSG database was reviewed for cases of secondary AML and for WT1 status of the affected patients. Referring institutions were contacted by a confidential letter requesting pathology reports, results of immunophenotyping, cytogenetic, and molecular analyses, and details concerning treatment of AML.
  
  
  RESULTS
  Of the 5,278 patients treated during the study period, 43 had second malignant neoplasms, and 7 of these 43 had AML. At the time of diagnosis of Wilms tumor, the median age of the seven patients (4 boys) was 3.2 years. Five of the seven renal neoplasms had favorable histologic characteristics. The most common French-American-British morphology was M5. One patient had bilateral tumors, and two were treated for recurrent Wilms tumor. All patients received chemotherapy regimens that included doxorubicin (6) or etoposide (1), and six were treated with infradiaphragmatic irradiation. The median latency period from initial diagnosis of the renal neoplasm to development of secondary AML was 3 years (range, 1.2-4 yrs). One patient had the translocation t(9:11)(p22;q23); WT1 status was not noted for any of the seven patients.
  
  
  CONCLUSIONS
  The development of secondary AML in this subset of patients after treatment of renal neoplasms may reflect the interaction of the effects of treatment and possible genetic predisposition toward cancer.
authors.affiliation: Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. patti.shearer@stjude.org
authors.forename: P
authors.initials: P
authors.lastname: Shearer
authors.forename: G
authors.initials: G
authors.lastname: Kapoor
authors.forename: J B
authors.initials: JB
authors.lastname: Beckwith
authors.forename: J
authors.initials: J
authors.lastname: Takashima
authors.forename: N
authors.initials: N
authors.lastname: Breslow
authors.forename: D M
authors.initials: DM
authors.lastname: Green
mesh_terms: D000015:Abnormalities, Multiple / Q000453:epidemiology; D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D015897:Comorbidity; D016208:Databases, Factual; D005260:Female; D005317:Fetal Growth Retardation / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000209:etiology; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D009396:Wilms Tumor / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy / Q000628:therapy*